TY - JOUR
T1 - Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin
AU - Kulengowski, Brandon
AU - Clark, Justin A.
AU - Burgess, David S.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/4
Y1 - 2019/4
N2 - Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.
AB - Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.
KW - Amikacin
KW - Carbapenem-resistant Enterobacteriaceae
KW - Meropenem
KW - Polymyxin B
KW - Time kill
UR - http://www.scopus.com/inward/record.url?scp=85057473215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057473215&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2018.10.020
DO - 10.1016/j.diagmicrobio.2018.10.020
M3 - Article
C2 - 30514595
AN - SCOPUS:85057473215
SN - 0732-8893
VL - 93
SP - 372
EP - 375
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 4
ER -
